|Table of Contents|

Relationship between metabolic syndrome and its components and the risk of prostate cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 16
Page:
3070-3075
Research Field:
Publishing date:

Info

Title:
Relationship between metabolic syndrome and its components and the risk of prostate cancer
Author(s):
ZHANG Mei; HUANG Weiling; TONG Luyao; LEI Liyi; LI Yingying
Health Management Center,Sichuan Provincial People's Hospital,University of Electronic Science and Technology of China,Sichuan Chengdu 610072,China.
Keywords:
metabolic syndrome; prostate cancer; cohort study; Cox regression model
PACS:
R737.25
DOI:
10.3969/j.issn.1672-4992.2023.16.024
Abstract:
Objective:To investigate the association between metabolic syndrome (MS) and its components and the risk of male prostate cancer.Methods:Based on the employees and retirees male unit work who conducted team health examination in the health management center of Sichuan Provincial People's Hospital from January 2014 to December 2016,a dynamic cohort of health examination was constructed.The baseline sociodemographic characteristics,MS and its components were collected through questionnaire survey,physical examination and laboratory testing,and the incidence and outcome of prostate cancer were followed up,Cox proportional hazards regression model was used to analyze the association between MS and its components and the risk of male prostate cancer.Results:Among the 293 872 subjects,the cumulative follow-up was 1 616 296 person years,with a median follow-up time of 6.15 years.During the follow-up period,there were 425 new cases of prostate cancer,and the overall incidence density was 26.29/100 000 person years.After adjusting for age and other confounding factors,compared with those with normal BMI,blood pressure and blood lipid,overweight and/or obese,hypertension and dyslipidemia have a significantly higher risk of prostate cancer ［aRR(95%CI) are 1.621(1.330~1.976),1.868(1.086~3.215) and 1.992(1.370~2.896)］ respectively.At the same time,compared with non MS patients,the risk of prostate cancer in MS patients was also significantly increased ［aRR(95%CI):1.998(1.353~2.951)］.With the increase of MS component,the cumulative incidence rate of prostate cancer also increased.χ2trend=216.747,P＜0.001).The ARR value of prostate cancer in the other three groups increased with the increase of the number of abnormal MS components.Conclusion:Overweight and/or obesity,hypertension,dyslipidemia and MS can increase the risk of male prostate cancer,and the risk of prostate cancer increases with the increase of the number of abnormal components of MS.Therefore,controlling body weight,maintaining normal BMI level and controlling blood pressure and blood lipid level in the normal range are effective primary preventive measures to reduce the risk of male prostate cancer in China.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］ RAWLA P.Epidemiology of prostate cancer［J］.World J Oncol,2019,10(2):63-89.
［3］ FAHED G,AOUN L,BOU ZERDAN M,et al.Metabolic syndrome:Updates on pathophysiology and management in 2021［J］.Int J Mol Sci,2012,23(2):786.
［4］ CULP MB,SOERJOMATARAM I,EFSTATHIOU JA,et al.Recent global patterns in prostate cancer incidence and mortality rates［J］.Eur Urol,2020,77(1):38-52.
［5］ CARLSSON SV,VICKERS AJ.Screening for prostate cancer［J］.Med Clin North Am,2020,104(6):1051-1062.
［6］ HIRODE G,WONG RJ.Trends in the prevalence of metabolic syndrome in the united states,2011-2016［J］.JAMA,2020,323(24):2526-2528.
［7］ BISHEHSARI F,VOIGT RM,KESHAVARZIAN A.Circadian rhythms and the gut microbiota:from the metabolic syndrome to cancer［J］.Nat Rev Endocrinol,2020,16(12):731-739.
［8］ MIYAHIRA AK,SHARP A,ELLIS L,et al.Prostate cancer research:The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting［J］.Prostate,2020,80(2):113-132.
［9］ 胡微薇，王志平.代谢综合征与泌尿系疾病相关性研究进展［J］.现代泌尿生殖肿瘤杂志,2016,8(3):183-185. HU WW,WANG ZP.Research progress on the correlation between metabolic syndrome and urinary diseases ［J］ Journal of Modern Urogenital Tumor,2016,8 (3):183-185.
［10］ 中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议［J］.中华糖尿病杂志，2004，12(3)：156-161. Metabolic Syndrome Research Collaboration Group,Diabetes Branch,Chinese Medical Association.Recommendations of diabetes branch of Chinese Medical Association on metabolic syndrome［J］ Chinese Journal of Diabetes,2004,12(3):156-161.
［11］ 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版) ［J］.中华健康管理学杂志，2017，11(1)：7-28. China Joint Committee on the Revision of Guidelines for the Prevention and Treatment of Adult Dyslipidemia.Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (revised in 2016) ［J］ .Chinese Journal of Health Management,2017,11(1):7-28.
［12］ BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
［13］ TEOH JYC,HIRAI HW,HO JMW,et al.Global incidence of prostate cancer in developing and developed countries with changing age structures［J］.PLoS One,2019,14(10):e0221775.
［14］ 李星，曾晓勇.中国前列腺癌流行病学研究进展［J］.肿瘤防治研究,2021,48(1):98-102. LI X,ZENG XY.Progress in epidemiology of prostate cancer in China ［J］ Cancer Prevention Research,2021,48(1):98-102.
［15］ 李蕊岑，陈吉祥，雷亚莉，等.前列腺癌相关危险因素研究进展［J］.实用医院临床杂志,2019,16(1):197-199. LI RC,CHEN JX,LEI YL,et al.Research progress in prostate cancer related risk factors ［J］ Clinical Journal of Practical Hospitals,2019,16(1):197-199.
［16］ MATSUSHITA M,FUJITA K,NONOMURA N.Influence of diet and nutrition on prostate cancer［J］.Int J Mol Sci,2020,21(4):1447.
［17］ DICKERMAN B,MUCCI L.Metabolic factors and prostate cancer risk［J］.Clin Chem,2019,65(1):42-44.
［18］ QIN X,QIU L,TANG G,et al.Prevalence of metabolic syndrome among ethnic groups in China［J］.BMC Public Health,2020,20(1):297.
［19］ GAO X,BAO T,YANG H,et al.The association of metabolic syndrome and its components with serum prostate-specific antigen levels［J］.Eur J Cancer Prev,2020,29(1):36-41.
［20］ LEE G,HAN K,LEE SS,et al.Different effect of obesity and metabolic syndrome on prostate cancer by age group［J］.Am J Cancer Res,2022,12(7):3198-3207.
［21］ LONGO A,RIBAS BLP,ORLANDI SP,et al.Prevalence of metabolic syndrome and its association with risk factors in patients with established atherosclerosis disease［J］.An Acad Bras Cienc,2020,92(1):e20180563.
［22］ MONROY-IGLESIAS MJ,RUSSELL B,CRAWLEY D,et al.Metabolic syndrome biomarkers and prostate cancer risk in the UK Biobank［J］.Int J Cancer,2021,148(4):825-834.
［23］ FUJITA K,HAYASHI T,MATSUSHITA M,et al.Obesity,inflammation,and prostate cancer［J］.J Clin Med,2019,8(2):201.
［24］ HUANG J,WEINSTEIN SJ,MOORE SC,et al.Pre-diagnostic serum metabolomic profiling of prostate cancer survival［J］.J Gerontol A Biol Sci Med Sci,2019,74(6):853-859.
［25］ DICKERMAN B,MUCCI L.Metabolic factors and prostate cancer risk［J］.Clin Chem,2019,65(1):42-44.

Memo

Memo:
国家重点研发计划子课题（编号：2017YFC0113901）；四川省科技厅重点研发项目（编号：2019YFS0278）；四川省卫计委课题（编号：20PJ107）
Last Update: 1900-01-01